393-55-5

Basic information

• Product Name: 2-Fluoronicotinic acid
• Synonyms: 2-FLUORO-3-PYRIDINECARBOXYLIC ACID;2-Fluoro-3-pyridinecarboxylic acid(2-Fluoronicotinic acid);2-FLUOROPYRIDINE-3-CARBOXYLIC ACID;2-FLUORONICOTINIC ACID;TIMTEC-BB SBB004159;RARECHEM AL BO 2399;2-Fluoro-3-NicotinicAcid;2-Fluoronicotinicacid,98+%
• CAS NO: 393-55-5
• Molecular Formula: C₆H₄FNO₂
• Molecular Weight: 141.1
• EINECS: 206-888-8
• Product Categories: Pyridine;Pyridines;Building Blocks;Carboxy;Fluoropyridines;Halopyridines;Carboxylic Acids;Boronic Acid;Picolinic acid series;C6;Chemical Synthesis;Fluorinated Building Blocks;Heterocyclic Building Blocks;Heterocyclic Fluorinated Building Blocks;Other Fluorinated Heterocycles;Morpholines/Thiomorpholines
• Mol File: 393-55-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 161-165 °C(lit.)
• Boiling Point: 298.7 °C at 760 mmHg
• Flash Point: 134.4 °C
• Appearance: White to yellow/Powder or Crystalline Powder
• Density: 1.419 g/cm³
• Vapor Pressure: 0.00713mmHg at 25°C
• Refractive Index: 1.533
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 2.54±0.10(Predicted)
• BRN: 3612
• CAS DataBase Reference: 2-Fluoronicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoronicotinic acid(393-55-5)
• EPA Substance Registry System: 2-Fluoronicotinic acid(393-55-5)

Safety Data

• Hazard Codes: Xi,F
• Statements: 36/37/38-10
• Safety Statements: 26-36-16
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 393-55-5(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow Cryst

Uses

2-Fluoronicotinic Acid is an intermediate used to prepare oxadiazole derivatives to inhibit tubulin polymerization and to cause mitotic arrest in tumor cells. It is also used to synthesize potent and selective inhibitors of human reticulocyte 15-lipoxygenase-1.

InChI:InChI:1S/C6H4FNO2/c7-5-4(6(9)10)2-1-3-8-5/h1-3H,(H,9,10)

Upstream product

• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 2369-18-8 2-fluoro-3-methylpyridine 
• 372-48-5 2-fluoropyridine 
• 124-38-9 carbon dioxide 
• 1603-40-3 3-methylpyridin-2-ylamine 

Downstream Products

• 446-26-4 methyl 2-fluoro-3-pyridinecarboxylate 
• 119899-26-2 2-fluoronicotinic acid chloride 
• 131747-55-2 2-fluoro-3-(hydroxymethyl)pyridine 
• 850263-09-1 2-fluoro-N-phenethyl-nicotinamide 
• 850263-15-9 N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N-methyl-2-(3-methyl-butoxy)-nicotinamide 
• 920986-88-5 2-fluoro-N-phenylnicotinamide 
• 1046468-61-4 C₁₃H₁₁FN₂O 
• 949154-26-1 2-fluoro-N-methoxy-N-methylpyridine-3-carboxamide 
• 1321924-70-2 (R)-2-((S)-4-(3-chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridine-3-yl)pyridine-2-yl)piperazin-2-yl)-3-methylbutan-2-ol 
• 609-71-2 2-hydroxy-3-carboxypyridine 
• 315180-14-4 3-(chloromethyl)-2-fluoropyridine 
• 120347-93-5 6-benzyl-6,7-dihydro-7-hydroxy-7-phenylpyrrolo<3,4-b>pyridin-5-one 
• 453563-30-9 N-(4-Trifluoromethylphenyl)-2-fluoronicotinamide 

Relevant articles and documents

Synthesis of some fluorine-containing pyridinealdoximes of potential use for the treatment of organophosphorus nerve-agent poisoning

Fluoroheterocyclic aldoximes were screened as therapeutic agents for the treatment of anticholinesterase poisoning. 2-Fluoropyridine-3- and -6-aldoxime, and 3-fluoropyridine-2- and -4-aldoxime, were synthesised. Attempts to obtain 3,5,6-trifluoropyridine-2,4-bis(aldoxime) and -2-aldoxime, however, proved unsuccessful. Pentafluorobenzaldoxime was prepared by oximation of pentafluorobenzaldehyde. Acid dissociation constants (pKa) and second-order rate constants (kox-) of the fluorinated pyridinealdoximes towards sarin were measured. 2,3,5,6-Tetrafluoropyridine-4- aldoxime had the best profile: its kox- approached that of the therapeutic oxime P2S (310 vs. 120 l mol-1 min-1), but its higher pKa (9.1 vs. 7.8) fell short of the target figure of 8 required for reactivation of inhibited acetylcholinesterase in vivo. N-alkylation of the fluorinated pyridine-aldoximes may reduce their pK a nearer to 8 and enhance their therapeutic potential. Crown Copyright

SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE

The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.

Substituted alkylamine derivatives and methods of use

Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.